Core Insights - Merck announced results from three pivotal Phase 3 trials for the investigational two-drug regimen doravirine/islatravir (DOR/ISL) for HIV-1 treatment, presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) [1] Group 1: Clinical Trial Results - The Phase 3 trial MK-8591A-053 showed DOR/ISL met its primary efficacy endpoint, achieving viral suppression in 91.8% of participants compared to 90.6% for the comparator BIC/FTC/TAF, demonstrating non-inferiority [2][3] - In the MK-8591A-052 and MK-8591A-051 trials, DOR/ISL maintained high rates of viral suppression at Week 96, with similar safety profiles to BIC/FTC/TAF and baseline antiretroviral therapy [3][10] - The safety profile for DOR/ISL remained consistent, with drug-related adverse events reported in 14.1% of participants on DOR/ISL compared to 18.0% on BIC/FTC/TAF [8][11] Group 2: Regulatory and Market Implications - The U.S. FDA has set a target action date of April 28, 2026, for the New Drug Application (NDA) for DOR/ISL, which could provide a new treatment option for adults living with HIV-1 [3][10] - DOR/ISL could serve as an important alternative for patients needing adjustments in their HIV treatment regimens due to comorbidities or tolerability challenges [4] Group 3: Mechanism and Future Developments - Islatravir, the active component in DOR/ISL, blocks HIV-1 replication through multiple mechanisms, including reverse transcriptase translocation inhibition [2][15] - Merck is evaluating islatravir in various combinations for potential daily and weekly treatments for HIV-1, indicating a robust pipeline for HIV treatment options [16][17]